Literature DB >> 9973205

Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation.

S S Hecht1, S G Carmella, M Chen, J F Dor Koch, A T Miller, S E Murphy, J A Jensen, C L Zimmerman, D K Hatsukami.   

Abstract

We quantified urinary levels of two metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in people who had stopped smoking: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and its O-glucuronide, 4-[(methylnitrosamino)-1-(3-pyridyl)but-1-yl]-beta-O-D-glucosiduronic acid (NNAL-Gluc). Twenty-seven people completed the study. Thirteen used the nicotine patch starting at the quit date, whereas the others used no patch. Two 24-h urine samples were collected on 2 consecutive days before smoking cessation; blood was also obtained. Beginning at their quit date, subjects provided 24-h urine samples on days 7, 21, 42, 70, 98, and 126, and some subjects also provided samples at later times. The urine was analyzed for NNAL, NNAL-Gluc, nicotine plus nicotine-N-glucuronide, and cotinine plus cotinine-N-glucuronide. Some blood samples were also analyzed for NNAL. The decline of urinary NNAL and NNAL-Gluc after smoking cessation was much slower than expected. This was clearly demonstrated by comparison with cotinine and nicotine levels in urine. One week after smoking cessation, 34.5% of baseline NNAL plus NNAL-Gluc was detected in urine, whereas the corresponding values for cotinine and nicotine were 1.1 and 0.5%, respectively. Even 6 weeks after cessation, 7.6% of the original levels of NNAL plus NNAL-Gluc remained. In some subjects, NNAL plus NNAL-Gluc were detected 281 days after cessation. The distribution half-life for NNAL and NNAL-Gluc was 3-4 days, whereas the elimination half-life was 40-45 days. Total body clearance of NNAL was estimated to be 61.4 +/- 35.4 ml/min, and volume of distribution in the beta-phase was estimated to be 3800 +/- 2100 liters, indicating substantial distribution into the tissues. Parallel studies in rats treated chronically or acutely with NNK in the drinking water support the conclusion that NNAL has a large volume of distribution. There was no effect of the nicotine patch on levels of NNAL plus NNAL-Gluc, indicating that NNK is not formed endogenously from nicotine. The results of this study demonstrate that NNAL and NNAL-Gluc are slowly cleared from the body after smoking cessation, indicating the presence of a high-affinity compartment where NNK, NNAL, and/or NNAL-Gluc are retained or sequestered and slowly released.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9973205

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  102 in total

1.  1,3-Butadiene exposure and metabolism among Japanese American, Native Hawaiian, and White smokers.

Authors:  Sungshim Lani Park; Srikanth Kotapati; Lynne R Wilkens; Maarit Tiirikainen; Sharon E Murphy; Natalia Tretyakova; Loïc Le Marchand
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-11       Impact factor: 4.254

2.  Comparing an immediate cessation versus reduction approach to smokeless tobacco cessation.

Authors:  Katherine R Schiller; Xianghua Luo; Amanda J Anderson; Joni A Jensen; Sharon S Allen; Dorothy K Hatsukami
Journal:  Nicotine Tob Res       Date:  2012-01-04       Impact factor: 4.244

3.  Smokeless tobacco reduction with the nicotine lozenge and behavioral intervention.

Authors:  Jon O Ebbert; Amanda Edmonds; Xianghua Luo; Joni Jensen; Dorothy K Hatsukami
Journal:  Nicotine Tob Res       Date:  2010-06-04       Impact factor: 4.244

4.  UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption.

Authors:  Jeannette Zinggeler Berg; Linda B von Weymarn; Elizabeth A Thompson; Katherine M Wickham; Natalie A Weisensel; Dorothy K Hatsukami; Sharon E Murphy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

5.  Effect of differing levels of tobacco-specific nitrosamines in cigarette smoke on the levels of biomarkers in smokers.

Authors:  David L Ashley; Richard J O'Connor; John T Bernert; Clifford H Watson; Gregory M Polzin; Ram B Jain; David Hammond; Dorothy K Hatsukami; Gary A Giovino; K Michael Cummings; Ann McNeill; Lion Shahab; Bill King; Geoffrey T Fong; Liqin Zhang; Yang Xia; Xizheng Yan; Joan M McCraw
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

6.  Self-reported Tobacco use does not correlate with carcinogen exposure in smokers with head and neck cancer.

Authors:  Samir S Khariwala; Steven G Carmella; Irina Stepanov; Dipankar Bandyopadhyay; Heather H Nelson; Bevan Yueh; Dorothy K Hatsukami; Stephen S Hecht
Journal:  Laryngoscope       Date:  2015-04-15       Impact factor: 3.325

Review 7.  Biomarkers to assess the utility of potential reduced exposure tobacco products.

Authors:  Dorothy K Hatsukami; Neal L Benowitz; Stephen I Rennard; Cheryl Oncken; Stephen S Hecht
Journal:  Nicotine Tob Res       Date:  2006-08       Impact factor: 4.244

8.  Smokeless tobacco brand switching: a means to reduce toxicant exposure?

Authors:  D K Hatsukami; J O Ebbert; A Anderson; H Lin; C Le; S S Hecht
Journal:  Drug Alcohol Depend       Date:  2006-09-20       Impact factor: 4.492

9.  Elimination kinetics of the tobacco-specific biomarker and lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol.

Authors:  Maciej L Goniewicz; Christopher M Havel; Margaret Wilson Peng; Peyton Jacob; Delia Dempsey; Lisa Yu; Wioleta Zielinska-Danch; Bartosz Koszowski; Jan Czogala; Andrzej Sobczak; Neal L Benowitz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

Review 10.  Clinical trials methods for evaluation of potential reduced exposure products.

Authors:  Dorothy K Hatsukami; Karen Hanson; Anna Briggs; Mark Parascandola; Jeanine M Genkinger; Richard O'Connor; Peter G Shields
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.